American multinational pharmaceutical company specializing in medications for cardiovascular diseases, cancer, diabetes, infectious diseases, and autoimmune disorders; major products include Eliquis and Opdivo.
Clinical Trials
171
41 active
Approvals
6
Total approvals
Agencies
1
Regulatory bodies
Founded
1933
Active, not recruiting
23
13.4%
Completed
52
30.4%
No Longer Available
1
0.6%
Not yet recruiting
18
10.5%
Recruiting
63
36.8%
Terminated
4
2.3%
- The EPO Boards of Appeal revoked EP 3 288 980, a BMS patent covering anti-PD-1 treatment of PD-L1-positive melanoma, in decision T 0715/24. - The Board ruled that combining a flat-dose regimen with nivolumab monotherapy extended beyond the content of the application as filed. - BMS also lost EP 3 322 731 after withdrawing its appeal, while the basic patent EP 2 161 336 remains protected by SPCs and data exclusivity until end of 2030. - Amgen's nivolumab biosimilar ABP 206 is in phase 3, with Sandoz, Intas and Accord also developing Opdivo biosimilars.
- Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts. - The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act. - Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act. - The legal action follows a 2024 U.S. Supreme Court loss for PhRMA, which had challenged the Arkansas law as unconstitutional on behalf of several manufacturers.
- Eli Lilly reported Q1 revenues of $19.8 billion, up 55.5% year-on-year, beating analyst estimates by 13.7% and posting the fastest revenue growth among branded pharma peers. - Merck delivered revenues of $16.29 billion, a 4.9% increase year-on-year, exceeding analyst expectations by 3% with a beat on EPS estimates. - Supernus Pharmaceuticals posted revenues of $207.7 million, up 38.6% year-on-year, driven by a 56% increase in combined growth product revenues, though EPS estimates were significantly missed. - The broader branded pharmaceuticals sector saw aggregate revenues beat consensus estimates by 3.6%, with tailwinds from precision medicine and AI adoption offset by pricing pressures and patent cliffs.
- The global EGFR inhibitors market reached USD 7 billion in 2025 across the 7MM, with the United States accounting for approximately 60% of total market share. - A wave of emerging therapies including zipalertinib, firmonertinib, ivonescimab, and multiple ADC candidates is expected to reshape the treatment landscape for EGFR-mutated cancers. - The FDA has set PDUFA action dates for ivonescimab (November 14, 2026) and zipalertinib (February 27, 2027), signaling imminent regulatory decisions for two novel agents. - EGFR exon 20 insertion mutations have emerged as a key competitive arena, with approvals of amivantamab and sunvozertinib creating a distinct market segment.
- Novavax reported Q1 revenues of $139.5 million, beating analyst estimates by 96.3% despite a 79.1% year-on-year decline, and announced a new Matrix-M license with Pfizer for up to two vaccine candidates. - Moderna posted $389 million in Q1 revenue, up 260% year-on-year and exceeding expectations by 55.8%, marking the fastest revenue growth among its therapeutic peers. - The 11 tracked therapeutics stocks collectively beat consensus revenue estimates by 15.6%, with share prices rising an average of 3.3% since reporting. - Eli Lilly delivered the standout pharmaceutical performance with $19.8 billion in revenue, up 55.5% year-on-year, surpassing analyst expectations by 13.7%.
- The US cardiovascular drugs market, valued at $28.42 billion in 2025, is forecast to grow to $37.03 billion by 2035 at a CAGR of 2.68%, according to Precedence Research. - Anticoagulants held the largest drug-type market share in 2025, while the antihypertensive segment is expected to grow fastest, fueled by lifestyle-related hypertension and FDA initiatives expanding OTC access. - RNA therapeutics, CRISPR-mediated gene editing, and AI-driven computational drug design are transforming cardiology by enabling targeted therapies for previously intractable lipid and metabolic pathways. - The Inflation Reduction Act is reshaping market dynamics by allowing Medicare to negotiate drug prices directly with manufacturers and capping annual out-of-pocket costs for beneficiaries.
- Oral squamous cell carcinoma accounts for over 370,000 new cases annually with 5-year survival rates of 50%–60%, driven by tobacco, alcohol, and rising HPV-linked cases. - PD-1 inhibitors nivolumab and pembrolizumab have demonstrated survival benefits in landmark trials including CheckMate-141 and KEYNOTE-048, particularly in PD-L1 CPS-positive patients. - Next-generation checkpoint targets such as LAG-3, TIGIT, and OX40 are being evaluated in early-phase trials, with eftilagimod alpha plus pembrolizumab showing a ~30% ORR in HNSCC. - Nanoparticle-based platforms including liposomes, polymeric nanoparticles, and gold-based systems offer enhanced drug delivery, immunomodulation, and chemo-immuno-photothermal synergies for OSCC.
- General Proximity, a San Francisco biotech company, received investment from FreeMind Investments and Daewoong Pharmaceutical for its innovative induced proximity medicine platform. - The company's proprietary OmniTAC platform scans the "effectome" to identify effector proteins that can modulate previously undruggable disease-causing targets. - General Proximity has secured over $20 million in funding, five "Golden Ticket" awards from major pharma companies, and a strategic collaboration with Daiichi Sankyo. - The investment reflects Daewoong Pharmaceutical's strategic interest in exploring future collaboration opportunities with General Proximity's platform technology.
- Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins, a distinguished biopharma leader with over 25 years of experience, as Strategic Adviser to advance its DCVax® dendritic cell-based cancer vaccine platform. - The company's lead program DCVax®-L for glioblastoma has completed a 331-patient Phase III trial and submitted a Marketing Authorization Application to the UK's MHRA for commercial approval. - The DCVax® platform is designed to address solid tumors, which represent approximately 90% of all cancers, with clinical trials encompassing 16 diverse tumor types. - Dr. Jenkins brings extensive expertise from executive roles at major pharmaceutical companies including Merck Serono and Bristol-Myers Squibb, plus experience as CEO of gene therapy company Dimension Therapeutics.
- Data from over 5,500 patients in the REMS program showed a low incidence of ejection fraction drop (4.6%) and heart failure hospitalization (1%). - Approximately 70% of patients achieved a left ventricular outflow tract gradient of less than 30 mmHg, indicating excellent efficacy with mavacamten. - The majority of patients experienced improved efficacy at doses of 5 or 10 mg, with few requiring the highest dose, demonstrating effective management. - Ongoing research explores new drugs like aficamten and EDG 7500, along with gene therapies, signaling a 'Renaissance age' for HCM treatment.
